Product Images Doxazosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Doxazosin NDC 68788-8412 by Preferred Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

TimelineDescription automatically generated - 2110EEC5 949D 4718 AD6D 3629E5DB8A07 00

TimelineDescription automatically generated - 2110EEC5 949D 4718 AD6D 3629E5DB8A07 00

This is a medication package of Doxazosin Tablets 4mg, a generic substitute for Cardura. Each tablet contains Doxazosin Mesylate, equivalent to 4 mg of doxazosin. The package is intended only for the patient for whom it was prescribed and cannot be transferred by law. The manufacturer is Apotex and Apolox, and the package contains 2x30 tablets. The lot number, batch number, and production number are also listed, along with the expiration date.*

doxazosin-structure.jpg - doxazosin structure

doxazosin-structure.jpg - doxazosin structure

figure1.jpg - figure1

figure1.jpg - figure1

table3.jpg - table3

table3.jpg - table3

This text contains data from different clinical trials regarding the effectiveness of doxazosin in treating benign prostatic hyperplasia (BPH). The trials include measurements of maximum flow rate and symptom score in patients treated with either doxazosin or a placebo. The results show that doxazosin is more effective than the placebo in improving symptoms and increasing maximum flow rate. The text includes information about the number of patients and the duration of the trials, as well as details about the dosages given.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.